首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions.
【24h】

Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions.

机译:禁食和进食条件下健康志愿者体内两种pan托拉唑肠溶制剂的生物等效性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To compare the bioavailability of two pantoprazole (CAS 102625-70-7) formulations (40 mg pantoprazole enteric coated tablets) under fasted and fed conditions as well as to evaluate the dissolution profile in biorelevant media. METHODS: The subjects received either 40 mg of the reference or of test formulation in fasting (n = 28) and fed (n=70) condition. The studies were conducted according to a single dose and randomized crossover design. Blood samples were collected up to 12 h after drug administration in fasting condition and up to 48 h in fed condition. Plasma concentrations of pantoprazole were determined by LC-MS/MS. Pharmacokinetic parameters were calculated from the observed plasma concentration-time profiles. Bioequivalence between the formulations in fasting and fed condition was assessed considering 90% confidence intervals for the ratio of means for lnCmax and lnAUC(0-t) within 0.8-1.25. Dissolution profiles were evaluated in biorelevant media [Fasting State Simulating Intestinal Fluid (FaSSIF) and Fed State Simulating Intestinal Fluid (FeSSIF)]. The sameness of the dissolution curves was assessed by f2 values between 50 and 100. RESULTS: Under fasting condition the 90% confidence interval for the ratio of means for the lnCmax, (0.94-1.03) and lnAUC(0-t) (0.89-0.99) was within the guideline range of bioequivalence (0.80-1.25). However, the data for lnCmax (0.51-0.76) and lnAUC(0-t) (0.68-0.90) under fed condition were not within the bioequivalence range. The postprandial study demonstrated a high intra-subject variability and in some subjects pantoprazole could not be detected for up to 24 h, although the dissolution profile of reference and test formulations presented a similar disposition in FaSSIF and FeSSIF as confirmed by the values of f2 higher than 50. CONCLUSION: The results demonstrated that the test formulation was bioequivalent to the reference in fasting condition but not in postprandial state. The dissolution profile in FaSSIF indicates that this biorelevant medium was more adequate to discriminate the in vivo disposition of pantoprazole than FeSSIF. Furthermore, the fed condition study had shown a pronounced influence of food in the absorption of pantoprazole after single oral dose administration.
机译:目的:在禁食和进食条件下比较两种pan托拉唑(CAS 102625-70-7)制剂(40 mg top托拉唑肠溶片)的生物利用度,并评估在生物相关介质中的溶出度。方法:受试者在禁食(n = 28)和进食(n = 70)的情况下接受40 mg参比制剂或测试制剂。根据单剂量和随机交叉设计进行研究。在禁食状态下给药后12小时和进食状态下48小时采集血样。通过LC-MS / MS测定pan托拉唑的血浆浓度。根据观察到的血浆浓度-时间曲线计算药代动力学参数。考虑到90%置信区间的lnCmax和lnAUC(0-t)均值之比在0.8-1.25之间,评估了禁食和进食条件下制剂之间的生物等效性。在生物相关介质中评估溶出曲线[快速模拟肠液(FaSSIF)和模拟快速肠液(FeSSIF)]。通过50至100之间的f2值评估溶出曲线的相同性。结果:在禁食条件下,lnCmax,(0.94-1.03)和lnAUC(0-t)(0.89- 0.99)在生物等效性的指导范围内(0.80-1.25)。但是,进食条件下lnCmax(0.51-0.76)和lnAUC(0-t)(0.68-0.90)的数据不在生物等效性范围内。餐后研究表明,受试者体内的变异性很高,在某些受试者中长达24小时仍未检测到pan托拉唑,尽管参考和测试制剂的溶出度在FaSSIF和FeSSIF中表现出相似的分布,f2值较高证实大于50。结论:结果表明,在空腹状态下,餐后状态下的测试制剂与参比制剂具有生物等效性。 FaSSIF中的溶出曲线表明,与FeSSIF相比,这种与生物有关的培养基更适合区分pan托拉唑的体内处置。此外,进食条件研究表明,单次口服给药后食物对pan托拉唑的吸收有显着影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号